Symbols / DTIL $7.91 +6.32% Precision BioSciences, Inc.

Healthcare • Biotechnology • United States • NCM
DTIL Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Fundamentals
Scroll to Statements
Market Cap 204.10M Enterprise Value 97.19M Income -46.61M Sales 34.26M Book/sh 3.83 Cash/sh 4.67
Dividend Yield — Payout 0.00% Employees 68 IPO — P/E — Forward P/E -2.42
PEG — P/S 5.96 P/B 2.07 P/C — EV/EBITDA -1.92 EV/Sales 2.84
Quick Ratio 12.97 Current Ratio 13.32 Debt/Eq 31.23 LT Debt/Eq — EPS (ttm) -3.63 EPS next Y -3.27
EPS Growth — Revenue Growth 52.61% Earnings 2026-05-15 ROA -22.41% ROE -62.71% ROIC —
Gross Margin 100.00% Oper. Margin 36.57% Profit Margin -133.45% Shs Outstand 25.80M Shs Float 19.58M Short Float 4.66%
Short Ratio 3.13 Short Interest — 52W High 8.82 52W Low 3.53 Beta 1.09 Avg Volume 270.90K
Volume 161.09K Target Price $32.00 Recom Strong_buy Prev Close $7.44 Price $7.91 Change 6.32%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$32.00
Mean price target
2. Current target
$7.91
Latest analyst target
3. DCF / Fair value
$-15.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.91
Low
$19.00
High
$60.00
Mean
$32.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-21 reit HC Wainwright & Co. Buy → Buy $60
2025-03-28 reit HC Wainwright & Co. Buy → Buy $60
2025-03-19 reit HC Wainwright & Co. Buy → Buy $60
2025-02-19 reit HC Wainwright & Co. Buy → Buy $60
2025-01-10 reit HC Wainwright & Co. Buy → Buy $60
2025-01-10 up BMO Capital Market Perform → Outperform $34
2024-05-30 reit HC Wainwright & Co. Buy → Buy $60
2024-05-16 reit HC Wainwright & Co. Buy → Buy $60
2024-04-30 init Guggenheim — → Buy $19
2024-04-17 reit HC Wainwright & Co. Buy → Buy $60
2024-03-28 main HC Wainwright & Co. Buy → Buy $60
2024-02-14 reit HC Wainwright & Co. Buy → Buy $3
News
RSS: Latest DTIL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 KELLY JOHN ALEXANDER Chief Financial Officer — 8,149 $3.84 $31,292
2026-02-18 SMITH J JEFFERSON Officer — 4,925 $3.84 $18,912
2026-02-18 SCIMECA DARIO JOSEPH General Counsel — 4,925 $3.84 $18,912
2026-02-18 AMOROSO MICHAEL Chief Executive Officer — 20,559 $3.84 $78,947
2026-02-17 KELLY JOHN ALEXANDER Chief Financial Officer — 27,584 — —
2026-02-17 SMITH J JEFFERSON Officer — 16,667 — —
2026-02-17 SCIMECA DARIO JOSEPH General Counsel — 16,667 — —
2026-02-17 AMOROSO MICHAEL Chief Executive Officer — 67,797 — —
2026-01-22 AMOROSO MICHAEL Chief Executive Officer — 34,799 $4.17 $145,112
2026-01-21 KELLY JOHN ALEXANDER Chief Financial Officer — 15,213 $4.03 $61,308
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
34.26
-50.12%
68.70
+40.98%
48.73
+94.15%
25.10
Operating Revenue
34.26
-50.12%
68.70
+40.98%
48.73
+94.15%
25.10
Operating Expense
86.41
-8.90%
94.86
+2.59%
92.46
+5.79%
87.41
Research And Development
54.17
-9.04%
59.56
+11.59%
53.38
+15.73%
46.12
Selling General And Administration
32.24
-8.67%
35.30
-9.69%
39.09
-5.32%
41.28
General And Administrative Expense
32.24
-8.67%
35.30
-9.69%
39.09
-5.32%
41.28
Other Gand A
32.24
-8.67%
35.30
-9.69%
39.09
-5.32%
41.28
Total Expenses
86.41
-8.90%
94.86
+2.59%
92.46
+5.79%
87.41
Operating Income
-52.15
-99.33%
-26.16
+40.18%
-43.74
+29.81%
-62.31
Total Operating Income As Reported
-52.15
-99.33%
-26.16
+40.18%
-43.74
+29.81%
-62.31
EBITDA
-42.43
-413.72%
13.53
+142.21%
-32.04
+48.97%
-62.79
Normalized EBITDA
-53.11
-239.38%
-15.65
+50.45%
-31.58
+38.57%
-51.41
Reconciled Depreciation
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
EBIT
-45.19
-604.94%
8.95
+122.21%
-40.30
+43.87%
-71.80
Total Unusual Items
10.67
-63.42%
29.17
+6428.42%
-0.46
+95.95%
-11.38
Total Unusual Items Excluding Goodwill
10.67
-63.42%
29.17
+6428.42%
-0.46
+95.95%
-11.38
Special Income Charges
-0.46
-4.82%
-0.44
+5.42%
-0.46
+95.76%
-10.87
Impairment Of Capital Assets
0.04
0.00
0.00
-100.00%
10.84
Write Off
—
—
0.00
-100.00%
10.84
Net Income
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Pretax Income
-46.61
-750.33%
7.17
+116.85%
-42.53
+41.67%
-72.91
Net Non Operating Interest Income Expense
2.82
-43.45%
4.98
-8.71%
5.46
+130.99%
2.36
Interest Expense Non Operating
1.42
-20.20%
1.78
-20.09%
2.23
+100.72%
1.11
Net Interest Income
2.82
-43.45%
4.98
-8.71%
5.46
+130.99%
2.36
Interest Expense
1.42
-20.20%
1.78
-20.09%
2.23
+100.72%
1.11
Interest Income Non Operating
4.24
-37.32%
6.76
-12.01%
7.69
+121.31%
3.47
Interest Income
4.24
-37.32%
6.76
-12.01%
7.69
+121.31%
3.47
Other Income Expense
2.72
-90.40%
28.35
+767.48%
-4.25
+67.24%
-12.96
Other Non Operating Income Expenses
-2.67
-1133.33%
0.26
-77.47%
1.15
—
Gain On Sale Of Security
11.13
-62.41%
29.61
+2486.03%
1.15
+324.51%
-0.51
Gain On Sale Of Business
—
—
—
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
6.13
0.00
0.00
Net Income Including Noncontrolling Interests
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Net Income From Continuing Operation Net Minority Interest
-46.61
-750.33%
7.17
+116.85%
-42.53
+41.67%
-72.91
Net Income From Continuing And Discontinued Operation
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Net Income Continuous Operations
-46.61
-750.33%
7.17
+116.85%
-42.53
+41.67%
-72.91
Net Income Discontinuous Operations
0.89
0.00
+100.00%
-18.79
+51.48%
-38.73
Normalized Income
-57.28
-260.70%
-15.88
+62.25%
-42.07
+31.63%
-61.52
Net Income Common Stockholders
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Diluted EPS
—
1.04
+106.52%
-15.96
+58.11%
-38.10
Basic EPS
—
1.05
+106.58%
-15.96
+58.11%
-38.10
Basic Average Shares
—
6.83
+77.88%
3.84
+31.11%
2.93
Diluted Average Shares
—
6.88
+79.20%
3.84
+31.11%
2.93
Diluted NI Availto Com Stockholders
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Earnings From Equity Interest
-5.28
-387.45%
-1.08
+78.02%
-4.93
-212.29%
-1.58
Gain On Sale Of PPE
-0.42
+3.44%
-0.44
+5.42%
-0.46
-1436.67%
-0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
154.42
+13.22%
136.39
-14.64%
159.78
-32.91%
238.17
Current Assets
118.74
+25.00%
94.99
-30.34%
136.36
-31.51%
199.10
Cash Cash Equivalents And Short Term Investments
115.58
+33.92%
86.31
-26.03%
116.68
-38.45%
189.58
Cash And Cash Equivalents
110.82
+29.02%
85.90
-26.38%
116.68
-38.45%
189.58
Other Short Term Investments
4.76
+1053.03%
0.41
0.00
—
Receivables
0.00
-100.00%
1.70
-86.73%
12.80
+1677.50%
0.72
Accounts Receivable
0.00
-100.00%
0.23
-74.58%
0.90
+25.14%
0.72
Other Receivables
—
1.47
—
—
Prepaid Assets
3.11
-51.72%
6.44
+7.76%
5.98
-0.80%
6.03
Assets Held For Sale Current
0.00
-100.00%
0.17
-65.30%
0.49
-68.70%
1.56
Other Current Assets
0.04
-87.80%
0.37
-11.93%
0.42
-65.88%
1.23
Total Non Current Assets
35.68
-13.82%
41.40
+76.75%
23.42
-40.04%
39.06
Net PPE
7.23
-28.97%
10.18
-30.29%
14.60
+5.97%
13.78
Gross PPE
35.92
-6.10%
38.26
-4.57%
40.09
+12.46%
35.65
Accumulated Depreciation
-28.69
-2.19%
-28.08
-10.15%
-25.49
-16.55%
-21.87
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.04
+0.00%
4.04
+2.20%
3.96
+0.20%
3.95
Construction In Progress
0.00
-100.00%
0.01
-87.14%
0.07
-86.54%
0.52
Other Properties
19.82
-10.64%
22.18
-8.06%
24.12
+25.39%
19.23
Leases
12.06
+0.30%
12.03
+0.69%
11.95
-0.01%
11.95
Goodwill And Other Intangible Assets
1.17
+87.46%
0.62
+55.50%
0.40
-45.28%
0.73
Other Intangible Assets
1.17
+87.46%
0.62
+55.50%
0.40
-45.28%
0.73
Investments And Advances
0.74
-76.79%
3.21
+0.00%
3.21
-32.48%
4.75
Long Term Equity Investment
—
—
0.00
-100.00%
2.17
Other Non Current Assets
26.54
+16.44%
22.79
+10028.89%
0.23
-98.21%
12.57
Total Liabilities Net Minority Interest
62.17
-22.29%
80.00
-43.23%
140.92
-20.71%
177.74
Current Liabilities
8.91
-40.50%
14.98
-70.03%
49.99
-16.22%
59.66
Payables And Accrued Expenses
2.01
-39.60%
3.33
-26.45%
4.53
+82.46%
2.48
Payables
0.30
-77.44%
1.31
-55.80%
2.97
+354.52%
0.65
Accounts Payable
0.30
-77.44%
1.31
-55.80%
2.97
+354.52%
0.65
Current Accrued Expenses
1.71
-14.98%
2.02
+29.48%
1.56
-14.78%
1.83
Pensionand Other Post Retirement Benefit Plans Current
4.75
-8.39%
5.18
+4.10%
4.98
-2.47%
5.10
Current Debt And Capital Lease Obligation
1.51
+14.17%
1.32
-94.39%
23.55
+1303.16%
1.68
Current Debt
—
—
22.41
—
Other Current Borrowings
—
—
22.41
—
Current Capital Lease Obligation
1.51
+14.17%
1.32
+16.50%
1.13
-32.48%
1.68
Current Deferred Liabilities
0.00
-100.00%
2.96
-75.43%
12.04
-73.95%
46.19
Current Deferred Revenue
0.00
-100.00%
2.96
-75.43%
12.04
-73.95%
46.19
Other Current Liabilities
0.65
-70.41%
2.19
-55.28%
4.90
+16.48%
4.21
Total Non Current Liabilities Net Minority Interest
53.26
-18.09%
65.02
-28.50%
90.93
-22.99%
118.07
Liabilities Heldfor Sale Non Current
—
—
0.13
-92.55%
1.72
Long Term Debt And Capital Lease Obligation
27.30
-4.96%
28.73
+271.94%
7.72
-66.83%
23.28
Long Term Debt
22.40
+0.37%
22.32
—
22.22
Long Term Capital Lease Obligation
4.90
-23.53%
6.40
-17.08%
7.72
+629.27%
1.06
Non Current Deferred Liabilities
10.00
-69.97%
33.30
-59.92%
83.08
-10.54%
92.87
Non Current Deferred Revenue
10.00
-69.97%
33.30
-59.92%
83.08
-10.54%
92.87
Other Non Current Liabilities
0.26
+33.51%
0.19
+51.56%
0.13
-36.32%
0.20
Stockholders Equity
92.25
+63.58%
56.39
+198.99%
18.86
-68.79%
60.43
Common Stock Equity
92.25
+63.58%
56.39
+198.99%
18.86
-68.79%
60.43
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
24.12
+193.03%
8.23
+96.36%
4.19
+12.49%
3.73
Ordinary Shares Number
24.09
+193.66%
8.20
+96.99%
4.16
+12.58%
3.70
Treasury Shares Number
0.03
-0.35%
0.03
+0.00%
0.03
0.00%
0.03
Additional Paid In Capital
621.39
+15.11%
539.81
+5.96%
509.44
+4.03%
489.70
Retained Earnings
-528.19
-9.48%
-482.46
+1.46%
-489.63
-14.32%
-428.31
Treasury Stock
0.95
+0.00%
0.95
+0.00%
0.95
+0.00%
0.95
Total Equity Gross Minority Interest
92.25
+63.58%
56.39
+198.99%
18.86
-68.79%
60.43
Total Capitalization
114.65
+45.66%
78.71
+317.34%
18.86
-77.18%
82.66
Working Capital
109.83
+37.27%
80.01
-7.37%
86.37
-38.06%
139.44
Invested Capital
114.65
+45.66%
78.71
+90.72%
41.27
-50.07%
82.66
Total Debt
28.81
-4.12%
30.05
-3.91%
31.27
+25.27%
24.96
Capital Lease Obligations
6.40
-17.09%
7.72
-12.78%
8.86
+223.57%
2.74
Net Tangible Assets
91.08
+63.31%
55.77
+202.10%
18.46
-69.08%
59.70
Tangible Book Value
91.08
+63.31%
55.77
+202.10%
18.46
-69.08%
59.70
Available For Sale Securities
0.74
-76.79%
3.21
+0.00%
3.21
+24.46%
2.58
Derivative Product Liabilities
15.70
+461.34%
2.80
0.00
—
Investmentin Financial Assets
0.74
-76.79%
3.21
+0.00%
3.21
+24.46%
2.58
Investments In Other Ventures Under Equity Method
—
—
—
—
Non Current Note Receivables
0.00
-100.00%
4.60
-7.78%
4.99
-31.02%
7.23
Notes Receivable
—
0.00
-100.00%
11.90
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-65.84
-12.66%
-58.45
+30.52%
-84.11
-83.84%
-45.75
Cash Flow From Continuing Operating Activities
-65.84
-12.66%
-58.45
+30.52%
-84.11
-83.84%
-45.75
Net Income From Continuing Operations
-45.72
-737.98%
7.17
+111.69%
-61.32
+45.07%
-111.64
Depreciation Amortization Depletion
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
Depreciation
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
Depreciation And Amortization
2.75
-39.85%
4.58
-44.55%
8.26
-8.32%
9.00
Other Non Cash Items
2.43
+445.03%
-0.70
-378.91%
-0.15
-132.67%
0.45
Stock Based Compensation
10.19
-19.18%
12.60
-10.23%
14.04
-26.86%
19.20
Asset Impairment Charge
0.04
0.00
-100.00%
0.64
-94.40%
11.44
Operating Gains Losses
-6.28
+77.65%
-28.09
-851.56%
-2.95
-275.19%
1.69
Gain Loss On Investment Securities
-11.13
+62.41%
-29.61
—
—
Unrealized Gain Loss On Investment Securities
—
-0.26
+77.47%
-1.15
—
Change In Working Capital
-29.24
+45.84%
-54.00
-30.16%
-41.49
-272.07%
24.11
Change In Receivables
1.70
-81.03%
8.95
+5046.41%
-0.18
+21.98%
-0.23
Changes In Account Receivables
0.23
-65.92%
0.67
+471.27%
-0.18
+21.98%
-0.23
Change In Prepaid Assets
3.33
+817.89%
-0.46
-144.15%
1.05
+209.25%
-0.96
Change In Payables And Accrued Expense
-0.74
+64.84%
-2.10
-238.99%
1.51
+885.62%
0.15
Change In Payable
-0.74
+64.84%
-2.10
-238.99%
1.51
+885.62%
0.15
Change In Account Payable
-0.74
+64.84%
-2.10
-238.99%
1.51
+885.62%
0.15
Change In Other Working Capital
-30.79
+45.85%
-56.87
-29.41%
-43.95
-260.64%
27.36
Change In Other Current Assets
0.34
+229.39%
-0.26
-114.95%
1.75
+22.43%
1.43
Change In Other Current Liabilities
-3.08
+5.46%
-3.26
-95.21%
-1.67
+54.10%
-3.64
Investing Cash Flow
-0.63
-194.88%
-0.21
-103.69%
5.83
+275.63%
-3.32
Cash Flow From Continuing Investing Activities
-0.63
-194.88%
-0.21
-103.69%
5.83
+275.63%
-3.32
Net PPE Purchase And Sale
-0.02
+90.00%
-0.19
+89.73%
-1.85
+44.26%
-3.32
Purchase Of PPE
-0.09
+66.00%
-0.25
+87.23%
-1.96
+41.04%
-3.32
Sale Of PPE
0.07
+10.00%
0.06
-43.93%
0.11
0.00
Capital Expenditure
-0.70
-154.55%
-0.28
+87.93%
-2.28
+31.36%
-3.32
Net Business Purchase And Sale
—
0.00
-100.00%
8.00
0.00
Gain Loss On Sale Of Business
-0.85
0.00
+100.00%
-8.45
0.00
Net Intangibles Purchase And Sale
-0.61
-2360.00%
-0.03
+92.21%
-0.32
0.00
Purchase Of Intangibles
-0.61
-2360.00%
-0.03
+92.21%
-0.32
0.00
Financing Cash Flow
95.16
+88.63%
50.45
+836.51%
5.39
-94.33%
94.98
Cash Flow From Continuing Financing Activities
95.16
+88.63%
50.45
+836.51%
5.39
-94.33%
94.98
Net Issuance Payments Of Debt
0.00
+100.00%
-0.04
0.00
-100.00%
19.80
Issuance Of Debt
0.00
-100.00%
22.47
0.00
-100.00%
19.80
Repayment Of Debt
0.00
+100.00%
-22.50
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
22.47
0.00
0.00
Long Term Debt Payments
0.00
+100.00%
-22.50
0.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-0.04
0.00
0.00
Short Term Debt Issuance
—
—
0.00
-100.00%
19.80
Net Short Term Debt Issuance
—
—
0.00
-100.00%
19.80
Net Common Stock Issuance
94.94
+88.99%
50.24
+907.58%
4.99
-93.29%
74.34
Proceeds From Stock Option Exercised
0.22
-12.45%
0.25
-37.91%
0.40
-51.98%
0.83
Net Other Financing Charges
—
—
—
—
Changes In Cash
28.68
+449.39%
-8.21
+88.74%
-72.90
-258.77%
45.91
Beginning Cash Position
108.47
-7.04%
116.68
-38.45%
189.58
+31.96%
143.66
End Cash Position
137.15
+26.45%
108.47
-7.04%
116.68
-38.45%
189.58
Free Cash Flow
-66.54
-13.32%
-58.72
+32.03%
-86.39
-76.05%
-49.07
Interest Paid Supplemental Data
1.35
-22.04%
1.74
-13.88%
2.02
+144.90%
0.82
Common Stock Issuance
94.94
+88.99%
50.24
+907.58%
4.99
-93.29%
74.34
Earnings Losses From Equity Investments
5.28
+387.45%
1.08
-78.02%
4.93
+212.29%
1.58
Issuance Of Capital Stock
94.94
+88.99%
50.24
+907.58%
4.99
-93.29%
74.34
Sale Of Business
—
0.00
-100.00%
8.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category